Kornimate/medical-research-clean huggingface dataset:
mechanisms linking depression to cardiovascular risk

Conditions: Depression; Cardiovascular Diseases; Heart Diseases

Summary: to examine the role of depression on risk for cardiovascular disease in twins.

background: multiple studies have demonstrated a higher risk of cardiovascular disease and worse cardiovascular disease (cvd) prognosis associated with depression that appear to synergistically and significantly adversely impact health. because these initial studies are observational, much work remains to understand this area. if these conditions are mechanistically inter-related, identification of both conditions in the same subject may provide a means of enhancing risk stratification and most appropriately targeting therapy. if the interaction between the conditions is causal not simply associative, appropriate therapy interventions can be designed and tested. design narrative: the project is designed to clarify the role of depression on cvd risk by using a co-twin study design. the study will examine twin pairs from the vietnam era twin registry (vet). twin pairs will be invited to participate if they meet two criteria: (1) neither has a history of cvd as of 1990 and (2) one twin is diagnosed with depression as of 1992. the study investigates the effects of depression on two indicators of "early" cvd: coronary flow reserve, assessed by means of positron emission tomography (pet) myocardial infusion imaging; and heart rate variability (hrv) assessed by ambulatory electrocardiographic monitoring. it is hypothesized that within each pair, the twins who have clinical depression will exhibit lower coronary vascular reserve and lower heart rate variability compared with their co-twins without a history of depression. moreover, by comparing the size of the intra-pair difference in these parameters between depression discordant monozygotic and dizygotic twins an estimate of the relative contributions of gene and environmental factors can be ascertained. in addition to the pet and hrv assessments, subjects will complete the statistical clinical interview of the diagnostic and statistical manual of mental disorders (dsm-iv scid) to document a history of depression, a psychometric battery including the early trauma inventory and hamilton depression scale, and such risk factors as cigarette smoking, physical activity, blood pressure and blood lipids, glucose and insulin, indices of inflammation and thrombogenicity including levels of reactive protein c, fibrinogen, and p-selectin, and neurohormones such as adrenocorticotropic hormone, cortisol, and dehydroepiandrosterone sulphate.

Eligibility criteria:
no eligibility criteria
gender-specific aeegs and outcome in preterms

Conditions: Gender Role Disorder, Male to Female Type

Summary: background and objectives: male sex is a risk factor for poor neurodevelopmental outcome following preterm birth. the investigators aimed to investigate gender-related differences in amplitude-integrated electroencephalography (aeeg) and to correlate these findings with neurodevelopmental outcome. methods: preterm infants born \<30 weeks' gestational age between 2000 and 2002 were prospectively included. aeegs obtained within the first two weeks of life were evaluated and classified according to background activity, sleep-wake cycling (swc) and seizure activity. outcome was assessed at three years.


Eligibility criteria:
inclusion criteria: * born\<30 weeks gestational age * who had aeegs in first 2 weeks of life * who were assessed for outcome at 3 years of age exclusion criteria: * born\>30 weeks gestational age * had no aeegs in first 2 weeks of life * lost for follow-up at 3 years
effect of blood pressure on cardiovascular outcomes and recurrence after catheter ablation in patients with atrial fibrillation

Conditions: Atrial Fibrillation, Persistent; Blood Pressure

Summary: effect of blood pressure on cardiovascular outcomes and recurrence after catheter ablation in patients with atrial fibrillation


Eligibility criteria:
inclusion criteria: the inclusion criteria were age \&gt;18 years and a diagnosis of af by electrocardiogram during the preceding six months or on admission exclusion criteria: no follow-up
an extension study investigating the efficacy and safety of a fast-dissolving ("melt") formulation of desmopressin for the treatment of nocturia in adults

Conditions: Nocturia

Summary: the purpose of this study was to investigate the long term efficacy and safety of several doses of the melt formulation of desmopressin in a broad population of adult patients with nocturia.

fe992026 cs31 was a multicenter open-label extension study for patients who were enrolled in study fe992026 cs29 (nct00477490) and had completed at least visit 3e in part ii of that study. the cs29 study was structured into 2 double-blind parts (part i and part ii). in part i, the initial 28-day treatment period, participants were randomly assigned to 1 of 5 treatment groups: placebo or desmopressin melt 10 μg, 25 μg, 50 μg, or 100 μg. immediately upon completion of part i of the study, all participants on active treatment continued into part ii on the same treatment for approximately 1 to 6 months. participants assigned to placebo in part i were randomly assigned to 1 of the 4 active treatments in part ii, based on re-randomization predetermined at the initial randomization (to maintain the blind). part ii began at the final visit for part i and continued until the database for part i was locked. therefore, treatment duration for part ii varied between 1 and 6 months, depending upon when the participant entered. upon completion of part ii of cs29, participants were given the option to participate in the open-label extension study (cs31). during cs31, each participant assigned to the 10 μg dose was switched to a higher dose in an open-label manner among the remaining 3 higher doses.

Eligibility criteria:
inclusion criteria: * written informed consent prior to the performance of any study-related activity. * was randomized into part ii of protocol fe992026 cs29 (nct00477490), entitled "a randomized, double blind,placebo controlled, parallel group, multi-center study with a double blind extension investigating the efficacy and safety of a fast-dissolving ("melt") formulation of desmopressin for the treatment of nocturia in adults" and have completed at least visit 3e in part ii (day 15). exclusion criteria: * patients using loop diuretics (furosemide, torsemide, ethacrynic acid).
efficacy of combination of trastuzumab to gemcitabine - platinum advanced or metastatic urothelial carcinoma

Conditions: Recurrent Bladder Cancer; Stage IV Bladder Cancer; Transitional Cell Carcinoma of the Bladder

Summary: a multicenter, randomized, phase 2 trial to study the effectiveness and feasibility of association of trastuzumab with combination chemotherapy in advanced or metastatic bladder cancer patients. combining monoclonal antibody therapy with combination chemotherapy may improve treatment efficacy on tumours overexpressed her 2.


Eligibility criteria:
inclusion criteria: * transitional cell carcinoma of the urothelium or bladder histologically proven stage iv ajcc \[locally advanced (t4b and / or n + m0) unresectable or metastatic (m1)\] * tumor and / or metastasis overexpressing her2 immunohistochemistry (ihc 3 +) or ihc 2 + and fish +. centralized analysis. * measurable disease with at least one lesion with a diameter\> 2 cm for conventional methods (clinical examination, ct or mri) or\> 1 cm for the helical scanner. in case of single metastasis, metastatic disease should be histologically proven * age ≥ 18 years and ≤80 years * life expectancy\> 3 months, * index performance status \<2 according to ecog ps, * no prior chemotherapy other than adjuvant and / or neoadjuvant chemotherapy, without herceptin ® and complete for more than 6 months (naive to any previous chemotherapy in the metastatic setting) * no radiotherapy within 4 weeks prior to inclusion, * normal cardiac function as measured by ejection fraction (lvef\> 50%), * blood and liver satisfactory constants: hematological criteria: - neutrophils\> 1.5 x 109 / l, - chips\> 100 x 109 / l - hemoglobin\> 10 g / dl, liver function: - alkaline phosphatase (unless bone metastases) \ 30 ml / min (cockcroft and gault, cf. annex xv protocol) - patient's written consent after full information. exclusion criteria: * concurrent treatment with an experimental drug, participation in another clinical trial within \<30 days * patients previously treated with herceptin ®, or another treatment targeting growth factors egf (eg iressa ®, tarceva ®) * existence of a severe pulmonary disease, liver or kidney is likely to be exacerbated by the treatment, * other medical conditions: congestive heart failure or angina pectoris even if medically controlled failure, history of myocardial infarction before entering the trial, hypertension or uncontrolled arrhythmias, significant valvular disease, * patient with dyspnoea at rest or requiring oxygen therapy or with respiratory failure, * presence of a severe infection requiring antibiotics, * presence of cns metastases or meningeal * history of another malignancy uncured or cured for less than 5 years (except basal cell carcinoma, papillary thyroid carcinoma in situ of the cervix treated) * pregnant or lactating or not using effective contraception women, * for cisplatin only: carrying a serious neurological disease, current events devices\> nci grade 2 neuropathy, hearing loss, creatinine clearance \<60 ml / min, the patient can not support a patient hydration.

Keywords: urothelial carcinoma trastuzumab treatment
rosacea prevalence in general population - pilot study

Conditions: Rosacea

Summary: the purpose of this study is to test and refine, a subject questionnaire aimed to be used in a general population rosacea prevalence study.

the study will test the subject questionnaire aimed to be used in a full general population prevalence study to screen potential subjects with rosacea. questionnaire will be self-administrated to dermatology outpatients. testing will be performed at the practice of 2 dermatologists experts in rosacea who will evaluate subjects' answers and propose fine-tuning of the questionnaire content, if needed.

Eligibility criteria:
* male or female aged between 18 (or locally accepted majority) and 65 years old both included. * subject visiting one of the study dermatology practices for daily care/routine dermatology consultation. * subject have to read and sign the approved informed consent form prior to any participation in the study, * subject willing and capable of cooperating to the extend and degree required by the protocol
effect of cinacalcet on parathyroid hormone secretion in children and adolescents with hypophosphatemic rickets

Conditions: Hypophosphatemic Rickets, X-Linked Dominant

Summary: this study will measure the effect of cinacalcet (sensipar) on parathyroid hormone (pth) secretion in children and adolescents with hypophosphatemic rickets (xlh). the investigators are seeking evidence that patients with xlh may benefit from treatment with cinacalcet by achieving better control of pth secretion.

x-linked hypophosphatemic rickets (xlh) is an x-linked dominant genetic disorder. common findings are low serum phosphate and inadequate 1,25(oh)2 vitamin d production. it is generally believed that the primary defect in xlh is impaired renal tubular transport of phosphate coupled with abnormal regulation of the enzyme responsible for the 1-alfa hydroxylation of 25(oh) vitamin d. the current treatment of children with xlh is large oral doses of phosphate and 1,25-dihydroxyvitamin d. there are two common side effects to this treatment; nephrocalcinosis and secondary hyperparathyroidism (hpt). the latter at times may cause hypertension, hypercalcemia, and permanent renal damage. the complication of secondary hyperparathyroidism is seen in 20% of the patients. the release of pth from the glands into the circulation is tightly regulated by serum calcium concentration. the glands "read" serum calcium concentration via ca sensing receptors (car) which are located at the surface of the glands. calcimimetics are compounds that allosterically modulate the car, thereby enhancing its sensitivity to circulating serum calcium concentrations and consequently decreasing pth secretion. when used in primary hpt, they rapidly reduce pth level and normalize serum calcium concentration. cinacalcet is a calcimimetic agent recently approved by the fda for treating hypercalcemia in patients with parathyroid carcinoma and secondary hpt in patients with chronic renal disease. cinacalcet was found to be effective in decreasing both pth level and the calcium x phosphorous ion product in dialysis patients. the goal of our proposed acute study is to see whether concomitant administration of cinacalcet and phosphate, to patients with xlh, will block completely or partially secretion of pth (day 2), expected to be seen following administration of phosphate alone (day 1). we will also monitor serum phosphate, total calcium, and ionized calcium concentration to learn to what extent, if any, blockage of pth secretion affects mineral homeostasis under this condition. if found to be effective in blocking pth secretion, cinacalcet will become a candidate for a long-term study in children with xlh to protect them from developing secondary hyperparathyroidism.

Eligibility criteria:
inclusion criteria: * established patients with xlh * age 5 years old and above * normal serum calcium and creatinine concentrations exclusion criteria: * patients with hypersensitivity to any component(s) of cinacalcet * hypocalcaemia * elevated serum creatinine

Keywords: cinacalcet pth xlh children and adolescents with hypophosphatemic rickets (xlh)
ecgi ibutilide: effect of ibutilide on af source location and organization

Conditions: Atrial Fibrillation; Persistent Atrial Fibrillation

Summary: this is a prospective, multi-center, non-randomized, un-blinded, observational trial.

this prospective, multicenter observational study will examine the ability of ecgi mapping to 1. effect of ibutilide on the number and size of the driver domains 2. effect of ablation of ibutilide-organized driver domains 3. effect of pv isolation on driver domains the researchers hypothesize that this approach will lead to successful arrhythmia control .

Eligibility criteria:
inclusion criteria: * ≥ 18 years of age. * ° symptomatic persistent af refractory or intolerant to at least 1 class i or iii antiarrhythmic medication persistent af - defined as persistent: af that is sustained \> 7 days. episodes of af which are terminated by electrical or pharmacologic cardioversion after ≥ 48 hours of af, but prior to 7 days, should also be classified as persistent af episodes. * planned to undergo first catheter ablation procedure ( prior atrial flutter typical is allowed) * ability to understand the requirements of the study and sign the informed consent form. * willingness to adhere to study restrictions and comply with all post-procedural follow-up requirements * projected lifespan greater than 1 year exclusion criteria: * they have baseline prolonged qt or renal failure precluding safe used of ibutilide * rheumatic heart disease, * current intra-cardiac thrombus, * history of mi or cabg within 6 weeks; * class iv hf, * unable to sign consent * projected lifespan of \< 1 year * women known to be pregnant or to have positive beta-hcg. * participation in another study that would interfere with this study. * unstable angina * recent cerebral ischemic events * contraindication to anticoagulation * prior history of polymorphic ventricular tachycardia or torsades de pointes

Keywords: atrial fibrillation persistent atrial fibrillation afib arrhythmia
rural engagement in primary care for optimizing weight reduction

Conditions: Obesity

Summary: the purpose of this study is to compare three methods for managing obesity in rural patients, to see which method will result in patients being able to attain their weight loss goal and maintain that weight loss.

nearly 20% of the u.s. population lives in rural communities. rural residents suffer at a higher rate from obesity and obesity-related illnesses, including diabetes, heart disease, and arthritis. local primary care physicians are an important resource for treating obesity in rural areas because of a lack of other community resources. this study is looking at how effective current, real-world primary care treatment models are in helping rural residents lose weight and maintain that weight loss. physician clinics will be randomized (like picking numbers from a hat) to conduct one of the three methods. the method a participant is part of will depend on the method their physician's clinic is randomized to. the three methods involved in this study are: 1. individual weight-management counseling in person (in clinic individual visits) 2. group weight-management counseling, both in person and by telephone; the latter if preferred by the group (in clinic group visits) 3. group weight-management counseling by telephone (phone group visits) participants will be in the study about 24 months. the number of in-person clinic visits and phone calls each participant will be asked to complete depends on the method.

Eligibility criteria:
inclusion criteria: * bmi between 30 kg/m2 and 45 kg/m2. * live in a rural location. * have clearance from their primary care provider to participate in a diet and exercise weight control intervention. * have access to a telephone. * one individual per household will be permitted to enroll in the study. exclusion criteria: * history of heart attack in the last six months, stroke in the last six months, or new cancer diagnosis in the last six months. * history of bariatric surgery or planning bariatric surgery in the next two years. * pregnancy within the last six months or planned within the next two years or currently pregnant or lactating. * serious medical conditions where weight loss is contraindicated. * end stage renal disease or end stage liver disease. * other medical contraindications as determined by the patient's primary care physician (pcp); documented pcp clearance will be obtained. * participants who are already enrolled in, or planning to enroll in another research study where weight loss is targeted. * participants who plan to relocate outside of their provider's service area or who plan to leave their primary care clinic in the next 2 years. * unable to read and understand english.

Keywords: weight loss weight management diabetes heart disease
arthroscopic-assisted reduction of hip dislocation via sub-adductor and anterolateral portals

Conditions: Developmental Dysplasia of the Hip

Summary: this study aims to present our arthroscopic-assisted surgical technique's reliability as a successful treatment for ddh, achieving reduction without the potential sequelae associated with open reduction techniques.

developmental dysplasia of the hip (ddh) encompasses a spectrum of pathological conditions including dislocation, subluxation, and deformities of the femoral head and acetabulum. the optimal surgical approach for ddh remains a subject of debate. the goal of successful treatment is achieving a stable concentric reduction and preventing future subluxation or dislocation.the aim of this study is to introduce the reliability of our arthroscopic-assisted surgical technique as a successful treatment for ddh that can achieve reduction with avoidance of sequelae which may be experienced following open reduction techniques.

Eligibility criteria:
inclusion criteria: - patients with ddh in this study exclusion criteria: - previous surgical treatment and those with teratologic or neuromuscular dislocations
temozolomide and concomitant whole brain radiotherapy in nsclc patients with brain metastases

Conditions: NSCLC

Summary: the purpose of this study is to evaluate the safety profile and efficacy of whole brain radiotherapy (wbrt) concomitantly with temozolomide (tmz) in patients with brain metastases (bm).patients with bm were randomly assigned to 30 gy of wbrt with or without concomitant tmz (75 mg/m2/d) plus two cycles of tmz (200 mg/m2/d for 5 days).


Eligibility criteria:
inclusion criteria: * histologically diagnosed as nsclc, stage ivb \[ (american joint of cancer committee(ajcc), 2002) \], brain metastasis * no history of hypertension or diabetes. exclusion criteria: * the brain tumor diameter \>5cm; rpa class =3; pregnancy.

Keywords: nsclc radiotherpy temozolomide
thoracoscopic wedge resection treated with chest tube removal intraoperatively

Conditions: Pain; Decreased Lung Function; Delayed Discharge

Summary: chest tubes are used routinely although preliminary studies demonstrate the feasibility and safety of intraoperative chest drain removal. previous studies are however either retrospective or mainly concerning benign disease. hypothesis: participants treated without post-operative chest tube after thoracoscopic wedge resection have less pain, better pulmonary function and similar complication profile than participants treated with standard post-operative chest tube, and could possibly be discharged earlier.


Eligibility criteria:
inclusion criteria: * elective thoracoscopic wedge resection * speaks and understands danish * fev1 \>= 60% of expected exclusion criteria: * increased risk of air leak evaluated by surgeon (large adhesions, bullae, emphysema, deep resection, etc.) * increased risk of bleeding evaluated by surgeon (high inr, anticoagulation not paused, large bleeding, etc.) * air leak on intraoperative sealing test * patients previously included in study * planned intraoperative frozen section with possible lobectomy * previously included in current study * planned frozen section diagnostics * previous ipsilateral anatomic lung resection

Keywords: lung neoplasm lung metastasis enhanced recovery after surgery fast-track surgery intraoperative chest tube removal pain lung function reasons for admission